Does Rallies show 13F holders for TECX?

Yes. Rallies tracks hedge fund and 13F ownership data for TECX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TECX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TECX. It does not provide personalized investment advice.

TECX (Tectonic Therapeutic, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Tectonic Therapeutic, Inc. Common Stock (TECX) is a publicly traded Healthcare sector company. As of May 21, 2026, TECX trades at $25.25 with a market cap of $522.68M and a P/E ratio of -6.89. TECX moved +5.61% today. Year to date, TECX is +46.32%; over the trailing twelve months it is +17.43%. Its 52-week range spans $13.70 to $61.07. Analyst consensus is strong buy with an average price target of $80.71. Rallies surfaces TECX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TECX stock?

Hedge funds tracked by Rallies that own TECX include Farallon Capital and Orbimed Advisors. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Tectonic Therapeutic, Inc. Common Stock.

TECX Key Metrics

Key financial metrics for TECX
Metric	Value
Price	$25.25
Market Cap	$522.68M
P/E Ratio	-6.89
EPS	$-4.05
Dividend Yield	0.00%
52-Week High	$61.07
52-Week Low	$13.70
Volume	1
Avg Volume	0
Revenue (TTM)	$-80.32M
Net Income	$-74.15M
Gross Margin	0.00%

Top Hedge Funds Holding TECX

Farallon Capital holds 1.28M shares of TECX, changed +0.00% as of Sep 30, 2025.
Orbimed Advisors holds 226.60K shares of TECX, changed -60.56% as of Mar 31, 2026.

Latest TECX News

Tectonic Therapeutic Secures $236.9M Runway and Advances TX45, TX2100 Trials — May 7, 2026
Tectonic Therapeutic Adds Jessica Chutter with $165B Deal Experience to Board — Apr 23, 2026
Tectonic Therapeutic Posts 29.2% PCWP Drop, Initiates PH-ILD and HHT Trials — Feb 26, 2026
Tectonic Therapeutic Begins Phase 1 Trial of TX2100 in HHT Patients — Feb 25, 2026

Recent TECX Insider Trades

Ruddy Marcella K. sold 1.06K (~$31.95K) on May 4, 2026.
Ruddy Marcella K. sold 1.00K (~$31.05K) on Apr 1, 2026.
Ruddy Marcella K. sold 10.00K (~$300.00K) on Mar 6, 2026.

TECX Analyst Consensus

8 analysts cover TECX: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $80.71.

Common questions about TECX

Who owns TECX stock?: Hedge funds tracked by Rallies that own TECX include Farallon Capital and Orbimed Advisors. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Tectonic Therapeutic, Inc. Common Stock.
Does Rallies show 13F holders for TECX?: Yes. Rallies tracks hedge fund and 13F ownership data for TECX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TECX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TECX. It does not provide personalized investment advice.